Tech Company Financing Transactions
Avidity Biosciences Funding Round
On 10/18/2018, Avidity Biosciences raised investment from CureDuchenne Ventures.
Transaction Overview
Company Name
Announced On
10/18/2018
Transaction Type
Venture Equity
Amount
Unknown
Round
Undisclosed
Investors
CureDuchenne Ventures (Debra Miller)
Proceeds Purpose
Funding will help to advance pre-clinical development of potential therapies to treat patients with Duchenne muscular dystrophy (DMD).
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
10975 North Torrey Pines Rd. 150
La Jolla, CA 92037
USA
La Jolla, CA 92037
USA
Phone
Website
Email Address
Overview
Avidity Biosciences LLC offers research, development, and manufacturing of drug candidates which include antibody-siRNA complexes.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Troy Wilson
Chief Executive Officer
Sarah Boyce
Chief Scientific Officer
Arthur Levin
Vice President
Andrew Geall
Vice President
John Wallen
VP - Bus. Development
Kent Hawryluk
VP - Finance
Vanessa Jacoby
Browse more venture capital transactions:
Prev: 10/18/2018: Oh My Green venture capital transaction
Next: 10/18/2018: BidMySmile venture capital transaction
Share this article
Where The Data Comes From
We do our best to record every notable VC transaction. VC investment data records on this site are sourced from a variety of public sources. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs